-
公开(公告)号:US10259821B2
公开(公告)日:2019-04-16
申请号:US15873571
申请日:2018-01-17
发明人: Ippei Sato , Takashi Kamikubo , Masanori Miura , Yuji Matsushima , Hiroaki Tanaka , Yasuhiro Shiina , Susumu Yamaki , Tomoyuki Saito , Hiroshi Kiyohara , Munemichi Ohe , Kayoko Mihara , Bradley Paul Morgan , Fady Malik , Scott Emile Collibee , Luke Ashcraft , Pu-Ping Lu , Jeffrey Michael Warrington , Marc Garard
IPC分类号: C07D491/20 , C07D491/107 , C07D471/04 , C07D471/10 , C07D217/24 , C07D217/26
摘要: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.
-
公开(公告)号:US20180148458A1
公开(公告)日:2018-05-31
申请号:US15873571
申请日:2018-01-17
发明人: Ippei Sato , Takashi Kamikubo , Masanori Miura , Yuji Matsushima , Hiroaki Tanaka , Yasuhiro Shiina , Susumu Yamaki , Tomoyuki Saito , Hiroshi Kiyohara , Munemichi Ohe , Kayoko Mihara , Bradley Paul Morgan , Fady Malik , Scott Emile Collibee , Luke Ashcraft , Pu-Ping Lu , Jeffrey Michael Warrington , Marc Garard
IPC分类号: C07D491/20 , C07D491/107 , C07D471/04 , C07D471/10 , C07D217/24 , C07D217/26
CPC分类号: C07D491/20 , C07D217/24 , C07D217/26 , C07D471/04 , C07D471/10 , C07D491/107
摘要: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.
-
公开(公告)号:US09914741B2
公开(公告)日:2018-03-13
申请号:US15429738
申请日:2017-02-10
发明人: Ippei Sato , Takashi Kamikubo , Masanori Miura , Yuji Matsushima , Hiroaki Tanaka , Yasuhiro Shiina , Susumu Yamaki , Tomoyuki Saito , Hiroshi Kiyohara , Munemichi Ohe , Kayoko Mihara , Bradley Paul Morgan , Fady Malik , Scott Emile Collibee , Luke Ashcraft , Pu-Ping Lu , Jeffrey Michael Warrington , Marc Garard
IPC分类号: C07D491/20 , C07D471/10 , C07D471/04 , C07D217/26 , C07D491/107 , C07D217/24
CPC分类号: C07D491/20 , C07D217/24 , C07D217/26 , C07D471/04 , C07D471/10 , C07D491/107
摘要: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.
-
公开(公告)号:US20170267638A1
公开(公告)日:2017-09-21
申请号:US15480618
申请日:2017-04-06
发明人: Bradley Paul Morgan , Alex Muci , Pu-Ping Lu , Erica Anne Kraynack , Todd Tochimoto , David J. Morgans, JR.
IPC分类号: C07D213/75 , C07D417/12 , C07D513/04 , C07D491/04 , C07D487/04 , C07D417/10 , C07D401/12 , C07D401/10 , C07D295/26 , C07D271/113 , C07D263/48 , C07D261/14 , C07D239/42 , C07D211/56 , C07D417/00
CPC分类号: C07D213/75 , C07D211/56 , C07D239/42 , C07D261/14 , C07D263/48 , C07D271/113 , C07D295/26 , C07D401/10 , C07D401/12 , C07D417/00 , C07D417/10 , C07D417/12 , C07D487/04 , C07D491/04 , C07D513/04
摘要: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
-
公开(公告)号:US20190194220A1
公开(公告)日:2019-06-27
申请号:US16291481
申请日:2019-03-04
发明人: Ippei Sato , Takashi Kamikubo , Masanori Miura , Yuji Matsushima , Hiroaki Tanaka , Yasuhiro Shiina , Susumu Yamaki , Tomoyuki Saito , Hiroshi Kiyohara , Munemichi Ohe , Kayoko Mihara , Bradley Paul Morgan , Fady Malik , Scott Emile Collibee , Luke Ashcraft , Pu-Ping Lu , Jeffrey Michael Warrington , Marc Garard
IPC分类号: C07D491/20 , C07D471/10 , C07D217/26 , C07D491/107 , C07D217/24 , C07D471/04
摘要: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.
-
公开(公告)号:US09987279B2
公开(公告)日:2018-06-05
申请号:US15509394
申请日:2015-09-09
发明人: Shinobu Mori , Yusuke Kajihara , Hiroko Inamura , Takuya Hirata
IPC分类号: A61K31/506 , A61K31/40 , A61K31/136 , C07D401/14
CPC分类号: A61K31/506 , A61K31/136 , A61K31/40 , C07D401/14
摘要: The problem to be solved by the present invention is to provide a novel pharmaceutical composition for prevention and/or treatment of urinary incontinence, which differs from conventional drugs. The present invention provides a therapeutic agent for prevention and/or treatment of urinary incontinence having 1-[2-({[trans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methyl}amino)pyrimidin-5-yl]-1H-pyrrole-3-carboxamide or a salt thereof, as an active ingredient.
-
公开(公告)号:US09643925B2
公开(公告)日:2017-05-09
申请号:US14837201
申请日:2015-08-27
发明人: Bradley Paul Morgan , Alex Muci , Pu-Ping Lu , Erica Anne Kraynack , Todd Tochimoto , David J. Morgans, Jr.
IPC分类号: C07D213/75 , C07D417/00 , C07D417/10 , C07D417/12 , C07D513/04 , C07D401/10 , C07D401/12 , C07D271/113 , C07D487/04 , C07D295/26 , C07D491/04 , C07D261/14 , C07D211/56 , C07D239/42 , C07D263/48
CPC分类号: C07D213/75 , C07D211/56 , C07D239/42 , C07D261/14 , C07D263/48 , C07D271/113 , C07D295/26 , C07D401/10 , C07D401/12 , C07D417/00 , C07D417/10 , C07D417/12 , C07D487/04 , C07D491/04 , C07D513/04
摘要: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
-
公开(公告)号:US09150564B2
公开(公告)日:2015-10-06
申请号:US14489705
申请日:2014-09-18
发明人: Bradley Paul Morgan , Alex Muci , Pu-Ping Lu , Erica Anne Kraynack , Todd Tochimoto , David J. Morgans, Jr.
IPC分类号: A61K31/54 , A61K31/535 , A61K31/44 , A61K31/445 , A61K31/497 , C07D417/12 , C07D401/12 , C07D213/75 , C07D211/56 , C07D239/42 , C07D261/14 , C07D263/48 , C07D271/113 , C07D295/26 , C07D401/10 , C07D417/10 , C07D487/04 , C07D491/04 , C07D513/04 , C07D417/00
CPC分类号: C07D213/75 , C07D211/56 , C07D239/42 , C07D261/14 , C07D263/48 , C07D271/113 , C07D295/26 , C07D401/10 , C07D401/12 , C07D417/00 , C07D417/10 , C07D417/12 , C07D487/04 , C07D491/04 , C07D513/04
摘要: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
-
公开(公告)号:US20140038983A1
公开(公告)日:2014-02-06
申请号:US13946353
申请日:2013-07-19
发明人: Bradley Paul MORGAN , Alex MUCI , Pu-Ping LU , Erica Anne KRAYNACK , Todd TOCHIMOTO , David J. MORGANS
IPC分类号: C07D213/75
CPC分类号: C07D213/75 , C07D211/56 , C07D239/42 , C07D261/14 , C07D263/48 , C07D271/113 , C07D295/26 , C07D401/10 , C07D401/12 , C07D417/00 , C07D417/10 , C07D417/12 , C07D487/04 , C07D491/04 , C07D513/04
摘要: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
摘要翻译: 某些取代的脲衍生物选择性地调节心肌肉瘤,例如通过增强心肌肌球蛋白,并且可用于治疗包括充血性心力衰竭的收缩性心力衰竭。
-
公开(公告)号:US20230125280A1
公开(公告)日:2023-04-27
申请号:US17944060
申请日:2022-09-13
发明人: Ippei SATO , Takashi KAMIKUBO , Masanori MIURA , Yuji MATSUSHIMA , Hiroaki TANAKA , Yasuhiro SHIINA , Susumu YAMAKI , Tomoyuki SAITO , Hiroshi KIYOHARA , Munemichi OHE , Kayoko MIHARA , Bradley Paul MORGAN , Fady MALIK , Scott Emile COLLIBEE , Luke ASHCRAFT , Pu-Ping LU , Jeffrey Michael WARRINGTON , Marc GARARD
IPC分类号: C07D491/20 , C07D491/107 , C07D217/24 , C07D471/04 , C07D217/26 , C07D471/10 , A61P21/00
摘要: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.
-
-
-
-
-
-
-
-
-